Intravenous immunoglobulin treatment of women with multiple miscarriages.
Eleven women who had previously experienced four to eight unexplained fetal losses (median 6.0 fetal losses/woman) were treated in their next pregnancy with individualized doses of pooled intravenous immunoglobulins. Nine women (82%) delivered healthy infants subsequent to the treatment. Prior to treatment, the pregnant patients had a significantly (P less than 0.05) increased median level of complement C3 neodeterminants in the blood compared with a group of 33 normal first trimester pregnant women. This may be a sign of increased turnover of complement in these women.
Christiansen
O B
OB
Department of Clinical Immunology, Aalborg Hospital, Denmark.
Mathiesen
O
O
Lauritsen
J G
JG
Grunnet
N
N
D000026:Abortion, Habitual / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D000328:Adult; D003176:Complement C3 / Q000378:metabolism; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy
D003176:Complement C3; D016756:Immunoglobulins, Intravenous